Countless numbers of animals, including mice, rabbits, dogs, and primates, continue to suffer and die in drug development. Yet research shows that 90 percent of new drugs tested on animals have failed in human clinical trials.
So why does animal testing continue?
Money could be a motivator. Last year, Inotiv, an animal supplier and contract research organization, said the 2022 FDA Modernization Act 2.0—a law requiring the Food and Drug Administration (FDA) to allow the use of non-animal methods in drug testing—could harm the company’s animal experimentation–centered business model. Since then, the FDA has failed to make meaningful regulatory changes, and although it announced plans in 2025 to reduce animal testing, its inaction maintains a reliance on animal-derived results that slow medical progress.
The FDA Modernization Act 3.0 could change that by requiring the FDA to update its drug development and testing regulations. Modern, non-animal methods can better predict human outcomes, reduce costs, and speed lifesaving treatments to patients, while also dramatically reducing animal suffering.
The FDA Modernization Act 3.0 has already unanimously passed in the Senate. Now it’s time to tell your representative in the House to support this important bill!
